Marksans Pharma Limited — Others, 11-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Marksans Pharma Limited confirmed there has been no deviation or variation in the utilization of funds raised through the preferential issue of convertible warrants. The total amount raised is ₹372.40 crore, aimed at strengthening the company's capital base and supporting its long-term financial resources for expansion. This statement, reviewed by the Audit Committee for the quarter ended December 31, 2024, reflects strong adherence to planned objectives, signaling operational stability and effective fund management. Investors may view this as a positive outlook, underscoring the company’s commitment to transparency and strategic growth plans.